{"id":6065,"text":"These authors contributed equally to this work.","label":[],"Comments":[]}
{"id":6066,"text":"These authors contributed equally to this work.","label":[],"Comments":[]}
{"id":6067,"text":"Galgeuntang (GGT), a traditional herbal medicine, is widely co-administered with acetaminophen (AAP) for treatment of the common cold, but this combination has not been the subject of investigation.","label":[[0,16,"Herb name"],[81,100,"Drug"],[122,133,"Pathology"]],"Comments":[]}
{"id":6068,"text":"Therefore, we investigated the herb–drug interaction between GGT and AAP by population pharmacokinetics (PKs) modeling and simulation studies.","label":[[61,65,"Herb name"],[69,73,"Drug"],[123,141,"Study"]],"Comments":[]}
{"id":6069,"text":"To quantify PK parameters and identify drug interactions, an open label, three-treatment, three-period, one-sequence (AAP alone, GGT alone, and AAP and GGT in combination) clinical trial involving 12 male healthy volunteers was conducted.","label":[[61,186,"Study"],[118,122,"Drug"],[129,133,"Herb name"],[144,148,"Drug"],[152,156,"Herb name"],[197,224,"Cohort"],[200,205,"Sex"],[205,213,"Pathology"]],"Comments":[]}
{"id":6070,"text":"Ephedrine (EPD), the only GGT component detected, was identified using a one-compartment model.","label":[[0,15,"Herb name"],[26,30,"Herb name"]],"Comments":[]}
{"id":6071,"text":"The PKs of AAP were described well by a one-compartment model and exhibited two-phase absorption (rapid followed by slow) and first-order elimination.","label":[[11,15,"Drug"]],"Comments":[]}
{"id":6072,"text":"The model showed that EPD significantly influenced the PKs of AAP.","label":[[22,26,"Herb name"],[62,65,"Drug"]],"Comments":[]}
{"id":6073,"text":"The simulation results showed that at an AAP dose of 1000 mg × 4 times daily, the area under the concentration versus time curve of AAP increased by 16.4% in the presence of GGT compared to AAP only.","label":[[41,45,"Drug"],[53,60,"Amount"],[63,78,"Frequency"],[82,128,"Parameter"],[132,136,"Drug"],[174,178,"Herb name"],[190,194,"Drug"]],"Comments":[]}
{"id":6074,"text":"In conclusion, the PKs of AAP were affected by co-administration of GGT.","label":[[26,30,"Drug"],[68,71,"Herb name"]],"Comments":[]}
{"id":6075,"text":"Therefore, when AAP is combined with GGT, adverse effects related to overdose of AAP could be induced possibly.","label":[[16,20,"Drug"],[37,40,"Herb name"],[41,57,"Pathology"],[81,85,"Drug"]],"Comments":[]}
{"id":6076,"text":"Herbal medicines are widely used alone or in combination with synthetic drugs.","label":[],"Comments":[]}
{"id":6077,"text":"Co-administration of herbal medicines and synthetic drugs may result in drug interactions, which could affect efficacy of treatment [1].","label":[],"Comments":[]}
{"id":6078,"text":"Indeed, a large number of over-the-counter combinations of synthetic and herbal drugs is used to treat mild conditions, despite the dearth of data on their interactions.","label":[],"Comments":[]}
{"id":6079,"text":"Galgeuntang (GGT), a traditional herbal medicine, is extracted from the herbs Puerariae Radix, Ephedra sinica, Paeonia albiflora, Glycyrrhiza uralensis Fisch, Zingiber officinale Roscoe, Cinnamomum cassia, and Ziziphus jujuba.","label":[[0,17,"Herb name"],[78,93,"Herb name"],[95,109,"Herb name"],[111,128,"Herb name"],[130,157,"Herb name"],[158,185,"Herb name"],[186,204,"Herb name"],[210,225,"Herb name"]],"Comments":[]}
{"id":6080,"text":"According to Korean Herbal Pharmacopoeia (2013), puerarin, ephedrine, paeoniflorin, glycyrrhetic acid, and (6)-shogaol are confirmed as marker compounds of GGT.","label":[[13,20,"Ethnic group"],[49,57,"Herb name"],[59,68,"Herb name"],[70,82,"Herb name"],[84,101,"Herb name"],[106,118,"Herb name"],[156,159,"Herb name"]],"Comments":[]}
{"id":6081,"text":"As a result of its anti-inflammatory, anti-pyretic, analgesic [2], antioxidant [3], and anti-influenza virus [4] activities, GGT has been used to treat the common cold.","label":[[125,129,"Herb name"]],"Comments":[]}
{"id":6082,"text":"In addition, GGT has been reported to modulate atopic dermatitis [5] and chronic rhinosinusitis [6].","label":[[13,17,"Herb name"],[47,64,"Pathology"],[72,95,"Pathology"]],"Comments":[]}
{"id":6083,"text":"GGT is frequently co-administered with Tylenol (acetaminophen) to treat the common cold in East Asia.","label":[[0,4,"Herb name"],[39,62,"Drug"],[76,87,"Pathology"]],"Comments":[]}
{"id":6084,"text":"Although regulatory agencies approved both drugs based on their efficacy and safety, no clinical study of this combination has been conducted.","label":[[87,103,"Study"]],"Comments":[]}
{"id":6085,"text":"Herbal medicines contain a variety of components, making them susceptible to interactions with other drugs.","label":[],"Comments":[]}
{"id":6086,"text":"Such interactions can alter the pharmacokinetics (absorption, distribution, metabolism, and excretion) of co-administered drugs.","label":[],"Comments":[]}
{"id":6087,"text":"GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.","label":[[0,4,"Herb name"]],"Comments":[]}
{"id":6088,"text":"A number of in vitro studies investigated the influence of GGT and GGT components on cytochrome (CYP) 450 and predicted its drug interactions [7,8,9,10,11,12,13,14,15,16,17,18,19].","label":[[15,28,"Study"],[59,63,"Herb name"],[67,71,"Herb name"],[85,105,"Target"]],"Comments":[]}
{"id":6089,"text":"For example, GGT reportedly inhibits CYP2C19, CYP2D6, and CYP2E1 [16].","label":[[13,17,"Herb name"],[36,44,"Target"],[46,52,"Target"],[58,65,"Target"]],"Comments":[]}
{"id":6090,"text":"Glycyrrhetic acid completely inhibits CYP3A4 [12], and paeoniflorin inhibits the activity of CYP1A2 in vivo [17].","label":[[0,18,"Herb name"],[37,45,"Target"],[55,67,"Herb name"],[93,99,"Target"]],"Comments":[]}
{"id":6091,"text":"Wu et al.","label":[],"Comments":[]}
{"id":6092,"text":"[8] reported that ephedrine induces CYP1A2 activity.","label":[[18,28,"Herb name"],[36,43,"Target"]],"Comments":[]}
{"id":6093,"text":"Moreover, puerarin inactivates CYP2C19, CYP2D6, and CYP1A2 [10].","label":[[10,19,"Herb name"],[31,38,"Target"],[40,46,"Target"],[52,59,"Target"]],"Comments":[]}
{"id":6094,"text":"Acetaminophen (AAP) metabolism mainly occurs in the liver and a lesser extent in the kidney and intestine [20].","label":[[0,19,"Drug"]],"Comments":[]}
{"id":6095,"text":"AAP is primarily metabolized to AAP glucuronide and AAP sulfate, and with a minor fraction to N-acetyl-p-benzoquinone imine (NAPQI) [21].","label":[[0,4,"Drug"],[32,36,"Drug"],[52,56,"Drug"]],"Comments":[]}
{"id":6096,"text":"NAPQI is highly reactive and mediates AAP-related hepatotoxicity.","label":[[38,41,"Drug"],[50,64,"Pathology"]],"Comments":[]}
{"id":6097,"text":"Several CYP450 (CYP3A4, CYP1A2, CYP2D6, CYP2A6, and CYP2E1) were reported to convert AAP to NAPQI [21].","label":[[85,89,"Drug"]],"Comments":[]}
{"id":6098,"text":"Therefore, when GGT and AAP are co-administered, a potential herb–drug interaction might occur and be mediated by CYP450.","label":[[16,20,"Herb name"],[24,28,"Drug"],[114,120,"Target"]],"Comments":[]}
{"id":6099,"text":"It possibly results in increasing NAPQI level and consequently causes hepatotoxicity.","label":[[70,84,"Pathology"]],"Comments":[]}
{"id":6100,"text":"However, no clinical study has been performed to evaluate such interaction to date.","label":[[12,26,"Study"]],"Comments":[]}
{"id":6101,"text":"Therefore, our study was conducted to investigate the effect of GGT on PKs of AAP by performing population pharmacokinetics and simulation studies.","label":[[64,68,"Herb name"],[78,82,"Drug"],[128,146,"Study"]],"Comments":[]}
{"id":6102,"text":"GGT tablets (640 mg) were purchased from Kyungbang Pharmaceutical Company (394 Namdong-daero, Namdong-gu, Incheon, Republic of Korea).","label":[[0,4,"Herb name"],[13,19,"Amount"]],"Comments":[]}
{"id":6103,"text":"The solvent used in the extract was 100% H Twelve male healthy volunteers who met the inclusion and exclusion criteria participated in this study.","label":[[43,74,"Cohort"],[50,55,"Sex"],[55,63,"Pathology"]],"Comments":[]}
{"id":6104,"text":"The inclusion and exclusion criteria were provided in the Supplementary Material Table S1.","label":[],"Comments":[]}
{"id":6105,"text":"All participants gave their informed consent before participating the study.","label":[],"Comments":[]}
{"id":6106,"text":"The study was performed in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Daejeon Korean Hospital of Daejeon University (Project identification no.","label":[],"Comments":[]}
{"id":6107,"text":"DCDC_18_01, approved on 3 January 2018).","label":[],"Comments":[]}
{"id":6108,"text":"This open-label, three-treatment, three-period, one-sequence clinical trial involved 12 male healthy volunteers.","label":[[5,75,"Study"],[84,111,"Cohort"],[88,93,"Sex"],[93,101,"Pathology"]],"Comments":[]}
{"id":6109,"text":"Each participant received three treatments with a 7 ± 1-day washout period in-between.","label":[],"Comments":[]}
{"id":6110,"text":"The treatment schedule was as follows: period 1, (G1) single-dose AAP 500 mg (2 tablets); period 2, (G2) combination of AAP 500 mg (2 tablets) and GGT 640 mg (12 tablets); and period 3, (G3) single-dose GGT 640 mg (12 tablets).","label":[[54,65,"Frequency"],[66,70,"Drug"],[69,76,"Amount"],[120,124,"Drug"],[124,130,"Amount"],[147,151,"Herb name"],[151,157,"Amount"],[191,203,"Frequency"],[203,207,"Herb name"],[207,213,"Amount"]],"Comments":[]}
{"id":6111,"text":"A dose of 1000 mg AAP (equal to 2 tablets) was used in this study because in clinical practice, AAP is recommended at 1000 mg for the treatment of the common cold.","label":[[10,17,"Amount"],[18,22,"Drug"],[96,100,"Drug"],[118,125,"Amount"],[151,162,"Pathology"]],"Comments":[]}
{"id":6112,"text":"To enhance efficacy of AAP, GGT is suggested in combination with AAP, and the maximum recommended dose of GGT is 12 tablets per day.","label":[[23,26,"Drug"],[28,32,"Herb name"],[65,68,"Drug"],[106,110,"Herb name"]],"Comments":[]}
{"id":6113,"text":"Therefore, we applied this dose of GGT in our study.","label":[[35,39,"Herb name"]],"Comments":[]}
{"id":6114,"text":"After screening (days −28 to −1), participants underwent a baseline assessment (day 0).","label":[],"Comments":[]}
{"id":6115,"text":"All participants fasted from 10 p.m. on the night prior to the day of drug administration.","label":[],"Comments":[]}
{"id":6116,"text":"During period 1, participants were given the drug at 8 a.m. and resided in the study center for at least 7 h for sample collection.","label":[[104,108,"Duration"]],"Comments":[]}
{"id":6117,"text":"In periods 2 and 3, the subjects stayed in the center for at least 30 h for PK analysis.","label":[[67,72,"Duration"]],"Comments":[]}
{"id":6118,"text":"The study design is shown in Figure 1.","label":[],"Comments":[]}
{"id":6119,"text":"Blood samples were analyzed by high-performance liquid chromatography-tandem mass spectrometry (Agilent 1100 HPLC; AB Science API2000).","label":[],"Comments":[]}
{"id":6120,"text":"Analytes were detected by multiple reaction monitoring at 152.2 → 110.1, 471.2 → 135.2, 277.2 → 137, 503.2 → 341.2, 166.2 → 117.1, 417 → 267.1, and 426.3 → 175.1 (precursor → product m\/z) for AAP, glycyrrhetic acid, (6)-shogaol, paeoniflorin, EPD, puerarin, and domperidone (internal standard), respectively.","label":[[192,195,"Drug"],[196,214,"Herb name"],[220,227,"Herb name"],[229,241,"Herb name"],[243,246,"Herb name"],[248,256,"Herb name"]],"Comments":[]}
{"id":6121,"text":"The calibration curves for AAP and EPD were linear at 50 to 10,000 ng\/mL and 50 to 2500 ng\/mL, respectively (R Non-compartmental PK analysis was performed using Phoenix WinNonlin (version 8.2.0.4383, Certera LP).","label":[[27,31,"Drug"],[35,39,"Herb name"]],"Comments":[]}
{"id":6122,"text":"The PK parameters were compared between the two groups by Mann–Whitney U-test (IBM SPSS Statistics Version 24).","label":[],"Comments":[]}
{"id":6123,"text":"The level of statistical significance was set at α = 0.05 for all tests.","label":[],"Comments":[]}
{"id":6124,"text":"The area under the concentration–time profile curve from zero to the last time point (AUC A population PK analysis was conducted by nonlinear mixed-effects modeling (NONMEM, version 7.4.1).","label":[[4,51,"Parameter"],[86,89,"Parameter"]],"Comments":[]}
{"id":6125,"text":"PK parameters and interindividual and residual variabilities were estimated using first order conditional estimation with interaction.","label":[],"Comments":[]}
{"id":6126,"text":"The model was modified in a sequential manner to identify that which best fit the data.","label":[],"Comments":[]}
{"id":6127,"text":"The model was chosen based on the OFV and plots of goodness of fit.","label":[],"Comments":[]}
{"id":6128,"text":"IIV was described using an exponential error model (Equation (1)): After development of optimal AAP model, a covariate analysis was conducted to assess additional variables as determinants of the variability in the PK estimate.","label":[[96,100,"Drug"]],"Comments":[]}
{"id":6129,"text":"The co-administered drug (GGT) was considered a covariate.","label":[[26,29,"Herb name"]],"Comments":[]}
{"id":6130,"text":"Covariate was tested using forward selection (p < 0.05) and backward elimination (p < 0.01) processes with likelihood ratio test to determine whether GGT affects the PKs of AAP.","label":[[150,154,"Herb name"],[173,176,"Drug"]],"Comments":[]}
{"id":6131,"text":"The effect of GGT on PKs of AAP was tested by linear, exponential, and power function models.","label":[[14,18,"Herb name"],[28,32,"Drug"]],"Comments":[]}
{"id":6132,"text":"The differences between OFV of each model and the base model were calculated.","label":[],"Comments":[]}
{"id":6133,"text":"During forward selection, a covariate was selected if it showed at least a decrease of 3.84 in OFV.","label":[],"Comments":[]}
{"id":6134,"text":"In backward elimination, an increase of at least 6.64 unit of OFV was set as criteria for retaining a covariate.","label":[],"Comments":[]}
{"id":6135,"text":"The final model was validated by VPC and nonparametric bootstrapping.","label":[],"Comments":[]}
{"id":6136,"text":"The parameter estimates of the bootstrap samples were re-estimated and the median and 95% confidence intervals were compared with those estimated using the final model.","label":[],"Comments":[]}
{"id":6137,"text":"For VPCs, the estimated parameter and the final model were used to simulate 1000 data sets, and the observed data were overlaid on the simulated median and 90% prediction intervals.","label":[],"Comments":[]}
{"id":6138,"text":"To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg × 4 times (8 tablets) per day for treatment of the common cold [22,23].","label":[[63,67,"Drug"],[89,97,"Amount"],[121,128,"Amount"],[130,158,"Frequency"],[180,191,"Pathology"]],"Comments":[]}
{"id":6139,"text":"Twelve tablets of GGT 640 mg per day is the maximum recommended dose.","label":[[0,37,"Frequency"],[18,22,"Herb name"],[21,28,"Amount"]],"Comments":[]}
{"id":6140,"text":"Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg × 4 times daily + GGT 7680 mg once daily) in a week.","label":[[93,97,"Drug"],[97,104,"Amount"],[105,116,"Frequency"],[118,122,"Herb name"],[122,129,"Amount"],[130,140,"Frequency"],[147,151,"Drug"],[151,158,"Amount"],[160,174,"Frequency"],[177,181,"Herb name"],[181,188,"Amount"],[188,199,"Frequency"],[206,210,"Duration"]],"Comments":[]}
{"id":6141,"text":"The effect of GGT on the PKs of AAP was assessed by monitoring the AUC Among the components of GGT, only EPD (Ephedra sinica) was detected under our analysis.","label":[[14,18,"Herb name"],[32,36,"Drug"],[67,71,"Parameter"],[95,98,"Herb name"],[105,125,"Herb name"]],"Comments":[]}
{"id":6142,"text":"Therefore, we investigated the interaction between AAP and EPD.","label":[[51,55,"Drug"],[59,62,"Herb name"]],"Comments":[]}
{"id":6143,"text":"Figure 2 shows the mean plasma concentration versus (vs.) time profiles of AAP administered alone (group 1, G1) and AAP co-administered with GGT (group 2, G2).","label":[[75,79,"Drug"],[116,120,"Drug"],[141,145,"Herb name"]],"Comments":[]}
{"id":6144,"text":"Table 2 summaries PK parameters of AAP in the presence or absence of GGT according to non-compartmental analysis (NCA) results.","label":[[35,39,"Drug"],[69,73,"Herb name"]],"Comments":[]}
{"id":6145,"text":"The area under the concentration–time curve from time zero to infinity (AUC One- and two-compartment with first-order elimination and absorption were initially tested in development AAP model.","label":[[3,43,"Parameter"],[72,76,"Parameter"],[182,186,"Drug"]],"Comments":[]}
{"id":6146,"text":"The objective function values (OFV) of those models are listed in Table 3.","label":[],"Comments":[]}
{"id":6147,"text":"One-compartment model gave an OFV of 1493.","label":[],"Comments":[]}
{"id":6148,"text":"When two-compartment was applied, the OFV increased by 34.6 units comparing to one-compartment model.","label":[],"Comments":[]}
{"id":6149,"text":"Therefore, one-compartment was used in the next step.","label":[],"Comments":[]}
{"id":6150,"text":"Variety of absorption models was tested to describe absorption process of AAP.","label":[[74,77,"Drug"]],"Comments":[]}
{"id":6151,"text":"Gastric emptying (GE) was firstly modelled in absorption phase of AAP owing to the dependence of AAP absorption on rate of GE [24].","label":[[0,21,"Parameter"],[66,70,"Drug"],[97,101,"Drug"],[123,126,"Parameter"]],"Comments":[]}
{"id":6152,"text":"Another simple GE model was also taken into consideration due to sparse absorption data.","label":[[15,18,"Parameter"]],"Comments":[]}
{"id":6153,"text":"In which, absorption phase was modelled with two periods, initially rapid absorbed (represented by k In the covariate analysis, the effect of co-administration EPD on the principal PK parameters (apparent clearance (CL\/F), absorption rate (k Incorporation of EPD significantly reduced the interindividual variability (IIV) and OFV (p < 0.05).","label":[[160,164,"Herb name"],[196,221,"Parameter"],[223,239,"Parameter"],[259,263,"Herb name"]],"Comments":[]}
{"id":6154,"text":"IIV of V\/F and k The parameter estimates and 95% confidence intervals for the parameters were calculated (Table 5).","label":[],"Comments":[]}
{"id":6155,"text":"All estimates obtained from the final model were comparable to the bootstrap estimates (n = 1000) and were within the 95% bootstrap confidence intervals.","label":[],"Comments":[]}
{"id":6156,"text":"Figure 5 shows the result of visual predictive check (VPC) (n = 1000) for AAP.","label":[[74,77,"Drug"]],"Comments":[]}
{"id":6157,"text":"Overall, the VPC suggested that the final model adequately describes the distribution of AAP concentration.","label":[[89,93,"Drug"]],"Comments":[]}
{"id":6158,"text":"The simulated median represented the trend of the observed concentration.","label":[],"Comments":[]}
{"id":6159,"text":"In addition, the majority of the observed values fell within the 90% prediction intervals.","label":[],"Comments":[]}
{"id":6160,"text":"Simulations were performed 1000 times using the developed model to assess the effect of GGT on PKs of AAP.","label":[[88,92,"Herb name"],[102,105,"Drug"]],"Comments":[]}
{"id":6161,"text":"AAP at 1000 once a day or 1000 mg × 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.","label":[[0,4,"Drug"],[12,23,"Frequency"],[26,33,"Amount"],[35,49,"Frequency"],[97,101,"Herb name"],[102,109,"Amount"],[111,116,"Frequency"]],"Comments":[]}
{"id":6162,"text":"The drugs were given consecutively over 1 week.","label":[[34,46,"Duration"]],"Comments":[]}
{"id":6163,"text":"The result was provided in the Table 6.","label":[],"Comments":[]}
{"id":6164,"text":"The median predicted AAP plasma concentrations are shown in Figure 6 and Figure 7.","label":[[21,25,"Drug"]],"Comments":[]}
{"id":6165,"text":"AAP administered alone (1000 mg; Figure 6A) resulted in the following PK parameters: AUC We investigated the effect of GGT on PKs of AAP in 12 healthy males using a population PK modeling approach.","label":[[0,4,"Drug"],[24,31,"Amount"],[85,89,"Parameter"],[119,123,"Herb name"],[133,137,"Drug"],[140,156,"Cohort"],[143,151,"Pathology"],[151,157,"Sex"]],"Comments":[]}
{"id":6166,"text":"The PKs of AAP were best described by a one-compartment and first-order elimination and two-period absorption phases.","label":[[11,15,"Drug"]],"Comments":[]}
{"id":6167,"text":"EPD, the only component of GGT detected, was identified as a covariate in the model.","label":[[0,3,"Herb name"],[27,31,"Herb name"]],"Comments":[]}
{"id":6168,"text":"The CL\/F, V\/F, k In our study, GE was applied to describe absorption process of AAP due to the dependence of AAP absorption on the rate of GE [24].","label":[[31,34,"Parameter"],[80,84,"Drug"],[109,113,"Drug"],[139,142,"Parameter"]],"Comments":[]}
{"id":6169,"text":"A biphasic GE pattern was modelled, in which a fraction of total administered drug (f Since the dependence of AAP absorption on GE rate [24], absorption of AAP is susceptible to factors which can change GE rate, such as food or concomitant intake.","label":[[11,14,"Parameter"],[110,114,"Drug"],[128,131,"Parameter"],[156,160,"Drug"],[203,206,"Parameter"]],"Comments":[]}
{"id":6170,"text":"In this study, for GGT 7680 mg, a total of 12 tablets were co-administered with AAP.","label":[[19,23,"Herb name"],[22,30,"Amount"],[80,83,"Drug"]],"Comments":[]}
{"id":6171,"text":"Those of tablet intake was enough to stimulate gastro-intestinal (GI) mobility under fasting condition, so the k In our population PK result, GGT increased V\/F while it had no effect on CL\/F of AAP, and sequentially resulted in an increase in t An increase in t According to this equation, AR is 1.18 and 1.63 in AAP alone group and combined group (AAP + GGT), respectively.","label":[[142,146,"Herb name"],[194,197,"Drug"],[313,317,"Drug"],[349,353,"Drug"],[355,358,"Herb name"]],"Comments":[]}
{"id":6172,"text":"The extent of drug accumulation in AAP alone group is lower than that of combined group.","label":[[35,39,"Drug"]],"Comments":[]}
{"id":6173,"text":"It results in an increase in AUC of AAP in combined group comparing to that in AAP alone group at dose of 1000 mg × 4 times per day with an increase of approximately 116.4% of AUC A total of 1000 mg × 4 times per day of AAP was applied in the simulation scenario because it is the highest recommended dose of AAP for treatment of the common cold [22,23].","label":[[29,33,"Parameter"],[36,40,"Drug"],[79,83,"Drug"],[106,114,"Amount"],[116,132,"Frequency"],[176,180,"Parameter"],[191,198,"Amount"],[201,216,"Frequency"],[220,224,"Drug"],[309,313,"Drug"],[333,345,"Pathology"]],"Comments":[]}
{"id":6174,"text":"As reference, patients can use 1000 mg AAP every 6 h, and should not take more than 4000 mg in 24 h. In addition, AAP was reported to follow linear pharmacokinetics for doses of less or equal to 18 mg\/kg [31].","label":[[14,23,"Pathology"],[31,38,"Amount"],[39,43,"Drug"],[42,52,"Frequency"],[83,91,"Amount"],[114,118,"Drug"],[195,203,"Amount"]],"Comments":[]}
{"id":6175,"text":"Therefore, it is appropriate to extrapolate PKs of AAP 1000 mg × 4 times per day from AAP 1000 mg.","label":[[51,54,"Drug"],[55,62,"Amount"],[65,81,"Frequency"],[86,90,"Drug"],[90,97,"Amount"]],"Comments":[]}
{"id":6176,"text":"In addition to investigating the effect of EPD on PKs of AAP, we also checked the impact of AAP on PKs of EPD, in which AAP as perpetrator and EPD as victim.","label":[[43,47,"Herb name"],[57,60,"Drug"],[92,96,"Drug"],[106,109,"Herb name"],[120,124,"Drug"],[143,147,"Herb name"]],"Comments":[]}
{"id":6177,"text":"The NCA results and plot of concentration vs. time profile of EPD with\/without AAP was provided in Supplementary Materials Table S3 and Figure S1, respectively.","label":[[62,66,"Herb name"],[79,83,"Drug"]],"Comments":[]}
{"id":6178,"text":"NCA results showed that there was no statistically significant difference between two groups, (EPD alone) and (EPD + AAP) (p > 0.05).","label":[[95,99,"Herb name"],[111,115,"Herb name"],[117,120,"Drug"]],"Comments":[]}
{"id":6179,"text":"Therefore, AAP was concluded to have no effect on PKs of EPD.","label":[[11,15,"Drug"],[57,60,"Herb name"]],"Comments":[]}
{"id":6180,"text":"Pseudoephedrine (P-EPD), a stereoisomer of EPD, is widely combined with AAP in a fixed dose of many commercial products for treatment common cold, headache, fever, etc.","label":[[0,22,"Herb name"],[43,46,"Herb name"],[72,76,"Drug"],[134,145,"Pathology"],[147,155,"Pathology"],[157,162,"Pathology"]],"Comments":[]}
{"id":6181,"text":"[32].","label":[],"Comments":[]}
{"id":6182,"text":"P-EPD and EPD show a relatively similar in physiochemical properties, such as same solubility (8.26 mg\/mL for both) [33,34], similar lipophilicity (logP = 1.13 for EPD [35], 0.89 for P-EPD [36]), etc.","label":[[0,6,"Herb name"],[10,14,"Herb name"],[164,168,"Herb name"],[185,189,"Herb name"]],"Comments":[]}
{"id":6183,"text":"As physiochemical properties mainly govern PK properties of drugs in the body [37], PKs of P-EPD are comparable to PKs of EPD.","label":[[91,97,"Herb name"],[122,125,"Herb name"]],"Comments":[]}
{"id":6184,"text":"As EPD has effects on PKs of AAP, P-EPD could have an interaction with AAP.","label":[[3,7,"Herb name"],[29,32,"Drug"],[34,39,"Herb name"],[71,74,"Drug"]],"Comments":[]}
{"id":6185,"text":"Therefore, caution should be necessary when taking a combination of P-EPD and AAP, especially in multiple dosage regimen.","label":[[68,73,"Herb name"],[78,81,"Drug"]],"Comments":[]}
{"id":6186,"text":"This study had several limitations.","label":[],"Comments":[]}
{"id":6187,"text":"Movement of AAP from the stomach to the small intestine is a determinant of its absorption.","label":[[12,16,"Drug"]],"Comments":[]}
{"id":6188,"text":"In our study, subjects were fasted to exclude any effect of food on AAP absorption.","label":[[68,72,"Drug"]],"Comments":[]}
{"id":6189,"text":"However, food is typically consumed when a medicine is taken and the impact of food on AAP absorption should be taken into consideration.","label":[[87,91,"Drug"]],"Comments":[]}
{"id":6190,"text":"Moore et al.","label":[],"Comments":[]}
{"id":6191,"text":"[38] reported that food delays the absorption of AAP.","label":[[49,52,"Drug"]],"Comments":[]}
{"id":6192,"text":"In the fed condition, the T This study is the first study to describe the herb–drug interaction between GGT and AAP.","label":[[104,108,"Herb name"],[112,115,"Drug"]],"Comments":[]}
{"id":6193,"text":"The developed model is adequately described the PKs of AAP in presence or absence of GGT.","label":[[55,59,"Drug"],[85,88,"Herb name"]],"Comments":[]}
{"id":6194,"text":"Co-administered with GGT decreased k Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.","label":[[21,25,"Herb name"]],"Comments":[]}
{"id":6195,"text":"The following are available online at  Click here for additional data file.","label":[],"Comments":[]}
{"id":6196,"text":"Conceptualization, S.J.P., J.-w.C., Y.C.P., and H.-y.Y.","label":[],"Comments":[]}
{"id":6197,"text":"; data analysis, Q.T.T., H.-m.B., L.T.N., S.J.P., J.-w.C., Y.C.P., and H.-y.Y.","label":[],"Comments":[]}
{"id":6198,"text":"; performing clinical trial, S.J.P.","label":[],"Comments":[]}
{"id":6199,"text":"and Y.C.P.","label":[],"Comments":[]}
{"id":6200,"text":"; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.","label":[],"Comments":[]}
{"id":6201,"text":"; qualifying modeling S.J.","label":[],"Comments":[]}
{"id":6202,"text":"and H.-y.Y.","label":[],"Comments":[]}
{"id":6203,"text":"; writing—original draft preparation, Q.T.T., S.J.P., J.-w.C., Y.C.P., and H.-y.Y.","label":[],"Comments":[]}
{"id":6204,"text":"; writing—review and editing, Q.T.T., S.J.P., H.-m.B., L.T.N., D.T.C., H.V.N., J.-w.C., Y.C.P., and H.-y.Y.","label":[],"Comments":[]}
{"id":6205,"text":"All authors have read and agreed to the published version of the manuscript.","label":[],"Comments":[]}
{"id":6206,"text":"This study was supported by research funds from Chungnam National University (CNU) and also supported by Institute of Information & communications Technology Planning & Evaluation (IITP) grant funded by the Korea government (MSIT) (No.2020-0-01441, Artificial Intelligence Convergence Research Center (Chungnam National University)) and by a grant of the Korea Healthcare technology R&D Project, Ministry for Health & Welfare Affairs, Republic of Korea (grant number: HI15C0006) and by a grant of National Research Foundation of Korea (Grant number : NRF-2018R1C1B6007898), Republic of Korea.","label":[],"Comments":[]}
{"id":6207,"text":"The authors declare no conflict of interest.","label":[],"Comments":[]}
{"id":6208,"text":"Scheme of the clinical trial.","label":[[14,28,"Study"]],"Comments":[]}
{"id":6209,"text":"PK, pharmacokinetics.","label":[],"Comments":[]}
{"id":6210,"text":"Comparison of plasma concentration–time profiles of acetaminophen (AAP) after administration alone or co-administration with Galgeuntang (GGT).","label":[[51,71,"Drug"],[125,142,"Herb name"]],"Comments":[]}
{"id":6211,"text":"Each point represents the mean and standard deviation.","label":[],"Comments":[]}
{"id":6212,"text":"Scheme of the base model with two periods of absorption phase.","label":[],"Comments":[]}
{"id":6213,"text":"CL, clearance.","label":[],"Comments":[]}
{"id":6214,"text":"Goodness of fit plots of the final AAP model.","label":[[35,39,"Drug"]],"Comments":[]}
{"id":6215,"text":"Empty circle: observation, solid line: reference line (y = x line for individual predicted concentrations (IPRED) or predicted concentrations (PRED) vs. observation plots, y = 0 for Time or IPRED vs. conditional weight residual (CWRES) plots), dash line: regression line.","label":[],"Comments":[]}
{"id":6216,"text":"Visual predictive check (VPC) plot of the final model for AAP observations.","label":[[58,62,"Drug"]],"Comments":[]}
{"id":6217,"text":"Empty circles: observed AAP concentration; pink area: 95% confidence intervals of median predicted concentration; gray areas: 95% confidence intervals of 5th and 95th percentile predicted concentration.","label":[[24,28,"Drug"]],"Comments":[]}
{"id":6218,"text":"Simulation result of 1000 mg AAP administered alone (A) or co-administered with GGT (B) in a week.","label":[[20,29,"Amount"],[29,33,"Drug"],[80,84,"Herb name"],[92,97,"Duration"]],"Comments":[]}
{"id":6219,"text":"Black solid lines: median simulated concentration; shaded bands: 90% percent confidence interval for 1000 replicates simulation.","label":[],"Comments":[]}
{"id":6220,"text":"Simulation result of 1000 mg × 4 times per day of AAP administered alone (A) or co-administered with GGT (B) in a week.","label":[[21,28,"Amount"],[31,47,"Frequency"],[50,54,"Drug"],[101,105,"Herb name"],[113,118,"Duration"]],"Comments":[]}
{"id":6221,"text":"Black solid lines: median simulated concentration; shaded bands: 90% percent confidence interval for 1000 replicates simulation.","label":[],"Comments":[]}
{"id":6222,"text":"The content of major ingredients in Galgeuntang.","label":[[36,47,"Herb name"]],"Comments":[]}
{"id":6223,"text":"Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.","label":[[78,81,"Drug"]],"Comments":[]}
{"id":6224,"text":"AUC Model development of AAP.","label":[[0,4,"Parameter"],[25,28,"Drug"]],"Comments":[]}
{"id":6225,"text":"ΔOFV, change in objective function value.","label":[],"Comments":[]}
{"id":6226,"text":"Summary of covariate model building steps.","label":[],"Comments":[]}
{"id":6227,"text":"ΔOFV, change in objective function value; DF: degree of freedom; K Parameter estimates of the final covariate model and bootstrap result for AAP.","label":[[141,144,"Drug"]],"Comments":[]}
{"id":6228,"text":"COV NCA results of simulated AAP in steady state.","label":[[29,33,"Drug"]],"Comments":[]}
{"id":6229,"text":"* AUC","label":[[2,5,"Parameter"]],"Comments":[]}
